$4M At-the-Market Placement for bioAffinity Technologies Closes…

Event summary

$4M private placement closed for bioAffinity Technologies via pre-funded warrants under Nasdaq rules.
8,462,027 shares of common stock purchasable through warrants issued at $0.4657 per unit.
Proceeds estimated at $4M before fees and expenses; WallachBeth Capital acted as sole placement agent.

The big picture

This $4M placement reflects the ongoing challenge for early-stage biotechs to secure non-dilutive financing. While at-the-market offerings provide flexibility, they also signal potential liquidity constraints. The deal underscores WallachBeth Capital’s niche in healthcare-focused capital markets services, particularly for firms like bioAffinity operating in high-risk, high-reward diagnostic spaces.

What we're watching

Liquidity Needs: Whether bioAffinity can sustain operations with this capital infusion amid high cash burn typical in diagnostic development.
Market Conditions: How Nasdaq's at-the-market rules impact future financing flexibility for small-cap biotechs.
Warrant Exercise: The pace at which warrants are exercised, signaling investor confidence in bioAffinity’s long-term viability.